Skip to main content

Table 4 Clinical information for irAE group

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

No. irAE CTCAE grade Onset date Nivolumab line Duration of treatment with nivolumab Treatment Outcome
1 Diarrhea/colitis 1 60 5 228 Symptomatic therapy Improved
Appetite loss 2 158     
2 Pruritus 1 28 5 72 Observation Improved
Edema limbs 1 28    Symptomatic therapy Improved
QTc interval prolonged 1 42    Observation Improved
3 Type 1 DM/Hyperglycemia 3 407 4 974 Insulin injection + DPP4 inhibitor Improved
4 Pruritus 1 72 6 902 Observation Improved
Hypothyroidism 1 167    Thyroid hormone Improved
Type 1 DM/Hyperglycemia 3 195    Insulin injection Improved
5 Dry skin 1 29 5 135 Observation Improved
Diarrhea/colitis 2 60    Corticosteroid Improved
6 Diarrhea/colitis 3 93 5 350 Corticosteroid Improved
7 Rash 1 11 4 266 Observation Improved
8 Diarrhea/colitis 1 33 3 140 Observation Improved
9 Peripheral motor neuropathy 3 3 5 107 Corticosteroid Improved
10 Rash 2 13 4 118 Corticosteroid Improved
Diarrhea/colitis 1 13     
11 Adrenal insufficiency 3 143 6 109 Corticosteroid Improved
12 Myalgia 2 16 3 194 Corticosteroid Improved
13 AST increased 3 28 3 147 Observation Improved
ALT increased 2 28    Observation Improved
14 Pneumonitis 3 32 4 63 Corticosteroid Stable
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, DM diabetes mellitus, DPP4 dipeptidyl peptidase, irAEs immune-related adverse events, QTc corrected QT
\